Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Accounts Payables (2017 - 2025)

Historic Accounts Payables for Dianthus Therapeutics (DNTH) over the last 8 years, with Q3 2025 value amounting to $6.7 million.

  • Dianthus Therapeutics' Accounts Payables fell 1145.01% to $6.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.7 million, marking a year-over-year decrease of 1145.01%. This contributed to the annual value of $4.6 million for FY2024, which is 7544.06% up from last year.
  • Dianthus Therapeutics' Accounts Payables amounted to $6.7 million in Q3 2025, which was down 1145.01% from $5.4 million recorded in Q2 2025.
  • In the past 5 years, Dianthus Therapeutics' Accounts Payables ranged from a high of $8.3 million in Q1 2025 and a low of $813000.0 during Q2 2023
  • In the last 4 years, Dianthus Therapeutics' Accounts Payables had a median value of $2.6 million in 2024 and averaged $3.7 million.
  • In the last 5 years, Dianthus Therapeutics' Accounts Payables crashed by 7566.47% in 2023 and then soared by 45310.45% in 2024.
  • Over the past 4 years, Dianthus Therapeutics' Accounts Payables (Quarter) stood at $1.2 million in 2022, then skyrocketed by 123.65% to $2.6 million in 2023, then skyrocketed by 75.44% to $4.6 million in 2024, then skyrocketed by 46.43% to $6.7 million in 2025.
  • Its Accounts Payables stands at $6.7 million for Q3 2025, versus $5.4 million for Q2 2025 and $8.3 million for Q1 2025.